<SEC-DOCUMENT>0001144204-16-133558.txt : 20161114
<SEC-HEADER>0001144204-16-133558.hdr.sgml : 20161111
<ACCEPTANCE-DATETIME>20161114062122
ACCESSION NUMBER:		0001144204-16-133558
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20161114
FILED AS OF DATE:		20161114
DATE AS OF CHANGE:		20161114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		161990221

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		5 HACHAROSHET ST.
		CITY:			RAANANA
		STATE:			L3
		ZIP:			4365603
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v452769_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of November, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: <B>001-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>XTL Biopharmaceuticals Ltd. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>5 HaCharoshet St., Raanana,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><BR>
4365603, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT> </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1023549|000114420416122986|image_001.jpg" STYLE="height: 77px; width: 255px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT><B>XTL
BIOPHARMACEUTICALS RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID REQUIREMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>RAANANA,
Israel</B></FONT><B> <FONT STYLE="font-size: 10pt">- (November 14, 2016) &ndash; <FONT STYLE="color: Blue"><U>XTL Biopharmaceuticals
Ltd</U></FONT><U>.</U> (NASDAQ: XTLB, TASE: XTLB.TA) </FONT></B><FONT STYLE="font-size: 10pt">(&ldquo;XTL&rdquo; or the &ldquo;Company&rdquo;),
</FONT>a clinical-stage biopharmaceutical company developing its lead product for the treatment of autoimmune diseases, today
announced that it received a notice from The NASDAQ Stock Market (&quot;NASDAQ&quot;) that the Company is not in compliance with
NASDAQ's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares (&ldquo;ADSs&rdquo;)
has closed below US$1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect
on the listing or trading of the Company's ADSs on The Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company has
180 days, or until May 8, 2017, to achieve compliance with the minimum bid price requirement. To regain compliance, the minimum
bid price of the Company's ADSs must meet or exceed US$1.00 per share for a minimum of 10 consecutive business days during this
180-day grace period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If the Company
does not regain compliance with the rule by May 8, 2017, the Company may be eligible for an additional 180 day compliance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About XTL Biopharmaceuticals Ltd.
(XTL)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL Biopharmaceuticals
Ltd., is a&nbsp;clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases including lupus. The Company&rsquo;s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of
systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some
have significant side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical
studies with data published in more than&nbsp;40 peer reviewed scientific journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL is&nbsp;traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><U>About hCDR1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">hCDR1 is a novel compound with a unique
mechanism of action and has clinical data on over 400 patients in three clinical studies. The drug has a favorable safety profile,
is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint. For more information
please see a peer reviewed article in Lupus Science and Medicine journal (http://lupus.bmj.com/content/2/1/e000104.full).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Systemic Lupus Erythematosus (SLE)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lupus is a chronic inflammatory autoimmune
disease involving many systems in the human body, including joints, kidneys, central nervous system, heart, hematological system
and others. The biologic basis of the disease is dysregulation of the immune (defense) system, leading to production of self (auto)
antibodies attacking the normal organs and causing irreversible damage. According to the Lupus Foundation of America, at least
1.5 million Americans have the disease (more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The
majority of patients are women of childbearing years. There has been only one drug approved by the FDA in the last 50 years and
recently two of the few drugs in advanced development did not meet their primary endpoints in Phase 3 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: ir@xtlbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">www.xtlbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Form F-1/A filed with the U.S. Securities
and Exchange Commission on November 8, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November&nbsp;14, 2016</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- /\# 2(  A$! Q$!_\0
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M:0K9NZ*6_>,G7VJ3P==7L^FL+QG?#_(S]<5)XKOCI]@)D178L!AJE\+W9O\
M31.R*K9QA:MN7U7X5:^_4S2C];^)WMMT-VBL[5M:L]'AWW#_ #'[J+U-<9=^
M.]0DD/V2*.)>P8;C44<)5K*\5H:5\91HNTGKV/1**\SB\;:Q&P\PQ.N>04P:
MZK1/%MKJCB"9?(N#T4GAOH:NK@*U)<S5UY$4<?0JRY4[/S.BHHHKC.T****
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MHYKQZ&E6/JCU*W\.7H?.P^Z*]D\-?$O0-)\/V=E<?:/.AC"MM3(S7E(T;4P
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M288SG J^D:QC"C%.HH @N+99QS2P6ZP+A:FHH 9)$L@PPS5"72(9"3@5I44
792:+$IR0*O0VL<(^4"IZ* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
